Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital.

Opinion | An Action Plan for Hypertension in Pregnancy

Graves is a high-risk ob/gyn and maternal-fetal medicine subspecialist. Tsigas is CEO of the Preeclampsia Foundation. There’s both tragedy and recognition in the recent headlines

September 25, 2024

New discovery unveils an additional layer of the CRISPR-Cas antiviral defense system

The recent publication in Science by Mogila, Tamulaitiene et al. represents a continuation of the successful scientific research conducted by Gintautas Tamulaitis’ group.

December 4, 2023

How the Eudēmonia Summit Has Already Improved My Life | Psychedelic Invest

And why everyone should go to this conference in 2025. I walked into the Palm Beach County Convention Center on November 1st bursting with curiosity.

November 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.